Vice President CMC and Technical Operations

Naveen Mallampati is an accomplished biopharmaceutical leader with over two decades of experience guiding complex drug products from development to commercialization. As Vice President of Chemistry, Manufacturing, and Controls (CMC) and Technical Operations at MedPharm, Mr. Mallampati leads cross-functional initiatives that strengthen the company’s pharmaceutical development, manufacturing, and supply chain capabilities.

With a strong focus on operational excellence and innovation, Mr. Mallampati is driving MedPharm’s strategic expansion into late-stage clinical development, regulatory submissions, and commercial product launches. His leadership is central to building GMP-compliant infrastructure, enhancing technical capabilities, and ensuring successful navigation of regulatory inspections.

Prior to joining MedPharm, Mr. Mallampati held leadership roles at leading pharmaceutical organizations including Tergus Pharma, Akorn, CPL, Patheon, Natco Pharma, and Dr. Reddy’s. His expertise spans product selection and lifecycle management, development optimization, and global commercialization strategies—all aimed at improving profitability and long-term growth.

Mr. Mallampati holds a Bachelor of Science in Pharmacy and an MBA with a focus in Pharmaceutical Management. He brings a unique blend of technical depth and business insight to MedPharm’s mission of delivering high-quality, innovative therapies to patients.

 

Senior Vice President of Pharmaceutical Development

Dr. Charles Evans serves as Senior Vice President of Pharmaceutical Development at MedPharm, with more than 20 years of experience in advancing products from early-phase through to commercialisation across topical, inhalation, transdermal, and injectable platforms. He has particular expertise in complex delivery systems designed to optimise drug efficacy, quality, and safety.

Throughout his career, Dr. Evans has led multidisciplinary teams in the design and optimisation of a broad range of dosage forms, including liquids, semi-solids, aerosols, and transdermal patches. He played a pivotal role in developing MedPharm’s proprietary MedSpray® technology, now licensed to enhance client product performance.

In his current role, he oversees global product development strategy and leads MedPharm’s UK centre of excellence for formulation development. Dr. Evans drives the delivery of robust, effective drug products, covering the full development lifecycle—from early formulation to scale-up and manufacturing—supported by a strong foundation in regulatory compliance and scientific rigour. His leadership helped establish MedPharm’s reputation for excellence in topical and transdermal drug delivery. He continues to contribute to the field through publications, patents, and active industry engagement.

Dr. Evans holds a PhD in Pharmacy from the University of Hertfordshire in the UK, where his research focused on novel spray-based treatments for dermatological conditions and MedPharm’s MedSpray® system.

Chief Scientific Officer

Dr. Jon Lenn is a seasoned life sciences executive with over 20 years of experience driving pharmaceutical innovation. As Chief Scientific Officer at MedPharm, he leads global research and development, overseeing the advancement of complex topical and transdermal drug products. Based in Durham, North Carolina, Jon has played a pivotal role in MedPharm’s growth since founding its US operations in 2015. Under his leadership, the company has pioneered cutting-edge biological models, novel test systems, and automation-driven drug development for challenging delivery routes, including dermal, respiratory, ophthalmic, ungual, and other mucosal applications.

 

Chief Executive Officer

Bill Humphries has served as the Chief Executive Officer of MedPharm since January 2025. Previously, Mr. Humphries led Alcami Corporation, a contract development and manufacturing organization, serving as its Chief Executive Officer and member of its board of directors from June 2023 to January 2025. From May 2021 to May 2023, Mr. Humphries served as the Chief Executive Officer of Isosceles Pharmaceuticals Inc., a biotechnology company. From 2018 to December 2020, Mr. Humphries served as President of Ortho Dermatologics, the dermatology division of Bausch Health Companies, Inc., and previously served as its Executive Vice President, Company Group Chairman for Dermatology and OraPharma from 2017 to 2018. From 2012 to 2016, he served as President and Chief Executive Officer of the North American business of Merz, Inc., an affiliate of Merz Pharma Group, a specialty healthcare company.